NeOnc Technologies Holdings Aktie
Marktkapitalisierung
103,51 Mio. $
103,51 Mio. $
Streubesitz
32,7%
KGV
-2,56
Index-Zuordnung
-
NeOnc Technologies Holdings, Inc. Common Stock Unternehmensprofil
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.
Vorstand
Herr Amir Farrokh Heshmatpour
Präsident, CEO, Vorstandsvorsitzender & Sekretärin
Dr. Thomas C. Chen M.D., Ph.D.
Gründer, Chief Medical Officer, Chief Scientific Officer & Stellvertretender Vorsitzender
Herr Keithly A. Garnett
Finanzvorstand
Dr. Josh Neman-Ebrahim Ph.D.
Chief Clinical Officer
Herr David Choi Jr.
Leiter des Rechnungswesens
Aktionärsstruktur
30,708%
Freefloat
19,454%
Individuelle Aktionäre
11,254%
Institutionelle Aktionäre
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway